| In millions, except per share items | Jun-30-23 | Mar-31-23 | Dec-31-22 | Sep-30-22 | Jun-30-22 | Mar-31-22 | Dec-31-21 | Sep-30-21 |
| | 10-Q | 10-Q | 10-K | 10-Q | 10-Q | 10-Q | 10-K | 10-Q |
| Revenue: | | | | | | | | |
| Total revenue | 766.7 | 866.9 | 680.4 | 665.0 | 689.4 | 704.3 | 492.3 | 498.9 |
| Total revenue growth | 11.2% | 23.1% | 38.2% | 33.3% | 100.6% | 156.5% | -40.8% | |
| Operating expenses: | | | | | | | | |
| Third-party medical costs | 769.6 | 708.3 | | | 541.3 | 535.8 | | |
| Direct patient expense | 56.8 | | | | 52.6 | | | |
| Selling, general, and administrative expenses | 99.4 | 96.5 | 107.8 | 111.8 | 106.2 | 96.6 | 93.3 | 76.6 |
| Depreciation and amortization expense | 27.3 | 27.2 | 26.4 | 25.3 | 19.8 | 19.0 | 18.7 | 17.0 |
| Transaction costs | 9.1 | 10.1 | 7.8 | 5.0 | 6.2 | 8.4 | 8.0 | 11.2 |
| Change in fair value of contingent consideration | -11.8 | -4.1 | 4.5 | 0.9 | -5.8 | -4.7 | -7.5 | -3.9 |
| Credit loss on other assets | 62.0 | | | | | | | |
| Total operating expenses | 1,012.4 | 906.4 | 1,042.9 | 696.5 | 720.4 | 715.8 | 534.5 | 532.5 |
| Income (loss) from operations | -245.6 | -39.5 | -362.6 | -31.4 | -31.0 | -11.5 | -42.3 | -33.6 |
| Operating margin | -32.0% | -4.6% | -53.3% | -4.7% | -4.5% | -1.6% | -8.6% | -6.7% |
| |
| Other income (expense): | | | | | | | | |
| Interest expense | -26.7 | -23.5 | -19.6 | -16.5 | -13.1 | -13.3 | -14.9 | -16.0 |
| Interest income | 0.1 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | | 0.0 |
| Loss on extinguishment of debt | | | | | | -1.4 | 0.1 | |
| Change in fair value of warrant liabilities | -1.7 | 2.0 | 81.2 | -65.7 | 30.2 | 27.2 | 58.3 | -14.7 |
| Other income (expense) | 1.3 | 0.4 | 0.8 | 0.4 | 0.3 | | 0.0 | 0.0 |
| Total other income (expense) | -27.0 | -21.1 | 62.4 | -81.8 | 17.3 | 12.5 | 43.5 | -30.7 |
| Net income (loss) before income tax expense | -272.6 | -60.6 | -300.2 | -113.3 | -13.8 | 1.0 | 1.3 | -64.3 |
| Income tax expense (benefit) | -1.9 | | 1.5 | -1.2 | 0.8 | 1.1 | 0.8 | 0.5 |
| Net income (loss) | -270.7 | -60.6 | -301.7 | -112.0 | -14.6 | -0.1 | 0.5 | -64.8 |
| Net income (loss) attributable to non-controlling interests | -130.0 | -32.4 | -153.4 | -57.8 | -9.2 | -0.7 | -0.2 | -41.6 |
| Net income (loss) attributable to Class A common stockholders | -140.8 | -28.2 | -148.4 | -54.2 | -5.3 | 0.7 | 0.7 | -23.2 |
| |
| Net income | ($0.51) | ($0.12) | ($0.67) | ($0.23) | ($0.03) | | | ($0.14) |
| Net income | ($0.51) | ($0.12) | ($0.67) | ($0.23) | ($0.03) | | ($0.12) | ($0.14) |
| |
| Weighted-average shares outstanding: | | | | | | | | |
| Basic (in shares) | 274.6 | 239.8 | 219.2 | 232.3 | 210.1 | 191.4 | 170.5 | 170.9 |
| Diluted (in shares) | 527.8 | 503.4 | 219.2 | 232.3 | 474.6 | 468.1 | 475.7 | 477.3 |